Today on Drug Discovery & Development
Insuring the trip: an underwriter on what it will take for approved psilocybin can become a real business
More than five decades after the Controlled Substances Act that President Richard Nixon signed in 1970 placed psilocybin in Schedule I, the same tier as heroin and reserved for drugs the federal government deemed to have no accepted medical use, the compound is on the verge of becoming the first classic psychedelic to win FDA…
How most-favored-nation pricing is reshaping generic drug economics, according to Dr. Reddy’s finance director
In the U.S. market, generics play a significant role in reducing overall drug spending. The FDA, for instance, estimated that the generics it approved in 2022 alone saved $18.9 billion in their first year on the market. Those savings come out of margins that keep thinning, because generic retail prices are in sustained deflation, as Brookings…
Drug Discovery and Development See More >
Top pharma companies set sustainability goals, but emissions are still increasing
The health care industry contributes an estimated 4.4% of total global emissions annually. Approximately 71% of this comes from the health care supply chain, which includes the pharmaceutical and biotechnology sectors. Medicines contribute approximately 20% to 55% of health care’s total carbon footprint. This comes from corporate emissions, API production and manufacturing. Pharmaceutical manufacturing is…
SLAS 2026: Orchestration patforms, API-first instruments and the rise of semiautonomous labs
How digital tools and AI are accelerating drug discovery
Pharma 2035 Playbook: Speed, focus and conviction in an uncertain world
STEERLife’s FragMelt platform manufactures drugs with heat sensitive active ingredient
Sponsored Content See More >
Top Automated Dispensing Cabinets for Pharmacies: Leading Brands ComparedSimplifying workflows is essential. Individuals in the pharmacy industry may accomplish more work with fewer errors by automating medication distribution.…
How Endogenous Tagging is Reshaping Protein AnalysisUnderstanding how proteins behave inside living cells is essential for modern drug discovery. Yet many widely used approaches, particularly plasmid…
What sets oncology biosimilars apart: Anticipating key challenges in the development landscapeBy Kimberly Salgado, ICON plc Advancements in biologic therapies have greatly improved our ability to treat cancer over the last…
Advancing Pressure Protection in Biopharma: How Integrated Bypass Technology Elevates Single-Use Pump Designby Michael Irving, Xylem In pharmaceutical and biopharmaceutical manufacturing, there is zero margin for error when it comes to process…
Complexity’s counterpoint: Understanding protocol optimization In recent years, the clinical research landscape has been marked by a steady rise in protocol complexity with more endpoints…
Optimizing Data Pipelines in Life Sciences with AI-Driven Integration and FHIRSponsored by Infor. Data management in life sciences is inherently complex. Data is fragmented across multiple systems — such…
Accelerating life sciences with AI This case study is sponsored by Infor. Artificial intelligence can revolutionize clinical interoperability by building bridges across data silos. Machine…
Advancing Clinical Trials and ResearchThis case study is sponsored by Infor. In the complex landscape of clinical trials and medical research, data fragmentation remains…
Multidisciplinary approaches optimize contract drug discovery
5 Key Questions in Conducting Global Usability StudiesBy Dr Bryce G Rutter, Head Noble Consulting Services Evaluating device usability throughout the product development process is crucial. A…
Leveraging HF/UX/ID Services to Optimize the Design of Combination Devices for Arthritic HandsBy Dr. Bryce G Rutter, Head of Consulting Services Arthritis changes how people grasp and manipulate an object, reducing the…
Ask the Expert: Navigating the New FDA Rules on Laboratory Developed Tests (LDTs)The U.S. FDA released a final rule to regulate laboratory developed tests (LDTs) on May 6, 2024, making it clear…
Genomics/Proteomics See More >
Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market
“I remember when we decided the internet was going to cure everything, and it didn’t…it came with a certain set of problems,” said Mark Bagnall, CEO of Phenomix Sciences. GLP-1s are having a similar moment, he says. GLP-1s have been transformative for many; by 2025, more than 30 million Americans were taking them for weight…
Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
Spatial biology: Transforming our understanding of cellular environments
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
Infectious Disease See More >
FDA refuses to review Moderna’s mRNA flu vaccine
Moderna received a refusal-to-file (RTF) letter from the FDA’s Center for Biologics Evaluation and Research (CBER) for its investigational mRNA vaccine for influenza, the company said Tuesday. The letter is inconsistent with the feedback received at pre-Phase 3 and pre-submission consultations, Moderna said. The company has requested a meeting with the FDA. The vaccine, mRNA-1010,…
Oncology See More >
Calderasib’s real innovation: designed for combination, not raw potency
Merck didn’t design calderasib to be the most potent KRAS G12C inhibitor on its own. It was designed to be the most combinable inhibitor. The KRAS gene encodes a protein that signals for cell growth. It cycles between active and inactive states, signaling when cells should divide. Although it is one of the most commonly…
Beyond PD-1: The drugs reshaping cancer treatment at ASCO 2026
BioNTech made €19B in 2021. This quarter: €118M. Now it’s cutting 1,860 jobs and betting €16.8B in cash on returning to its oncology roots.
UCLA researchers advance EGFR-targeted drug for glioblastoma into clinical testing
